Research Article
Economic Burden Analysis of Parkinson’s Disease Patients in China
Table 3
Univariate analyses of contributions of various factors to the cost of PD ($, 2016 values).
| Characteristics | | Mean | Median | | | Mean rank | |
| Sex | | | | | | | | Male | 72 | 2626.44 | 1141.15 | 587.03 | 3461.17 | 8.05 | | Female | 44 | 4206.96 | 1373.20 | 758.55 | 4491.21 | 9.04 | Age | | | | | | | | ≤60 years | 27 | 4193.49 | 1583.65 | 747.62 | 6880.35 | 9.55 | | 61–70 years | 48 | 2280.62 | 890.48 | 631.19 | 2413.64 | 7.73 | | ≥71 years | 41 | 3695.51 | 6295.98 | 513.73 | 4054.51 | 8.50 | | Duration of disease | | | | | | | | 1–5 years | 71 | 2075.92 | 796.02 | 536.57 | 1583.65 | 6.98 | | 6–10 years | 33 | 4600.23 | 2774.03 | 683.60 | 6006.25 | 9.75 | | >10 years | 12 | 6251.00 | 6209.40 | 1908.07 | 9664.85 | 13.31 | | Delayed diagnosis | | | | | | | ≤2 years | 91 | 3152.85 | 978.64 | 627.20 | 2921.30 | 8.06 | | ≤5 years | 18 | 2877.63 | 1208.53 | 584.61 | 5292.34 | 8.63 | | >5 years | 7 | 5071.96 | 2774.03 | 1822.18 | 9408.40 | 12.57 | | HY stage | | | | | | | HY I | 32 | 1055.23 | 749.72 | 425.56 | 1445.52 | 5.93 | | HY II | 37 | 1352.50 | 850.04 | 348.86 | 1480.91 | 6.72 | | HY III | 29 | 6917.09 | 3858.03 | 936.91 | 9293.66 | 11.14 | | HY IV | 9 | 6264.64 | 5379.19 | 1421.05 | 10206.00 | 12.78 | | HY V | 9 | 3713.63 | 4282.27 | 1541.82 | 5441.76 | 11.19 | | Past history | | | | | | | No | 86 | 2760.31 | 999.28 | 602.26 | 3902.76 | 8.11 | | Hypertension | 8 | 11643.62 | 5324.07 | 1012.57 | 18502.35 | 11.56 | | Diabetes | 4 | 1099.16 | 659.39 | 278.21 | 2359.87 | 5.26 | | Angiocardiopathy | 11 | 1778.42 | 1316.31 | 693.57 | 2723.36 | 8.51 | | CI | 7 | 2816.39 | 2687.50 | 958.62 | 4557.04 | 10.35 | | Surgical therapy | | | | | | | | No | 113 | 2468.63 | 1252.39 | 635.19 | 3741.53 | 8.21 | | Yes | 3 | 31751.49 | 2578.24 | 21196.31 | | 16.56 | | Antiparkinsonian drug levodopa costs | | | | | | | ≤455.625 | 41 | 2063.41 | 791.36 | 695.40 | 2023.34 | 7.51 | | ≤675 | 40 | 2675.48 | 1004.27 | 341.80 | 3587.03 | 7.73 | | ≤911.25 | 11 | 8073.97 | 4282.27 | 1019.93 | 8535.38 | 11.17 | | >911.25 | 21 | 3907.39 | 2426.61 | 685.98 | 5657.59 | 9.89 | | Dopamine agonists costs | | | | | | | 0 | 38 | 1672.29 | 427.42 | 277.88 | 2276.65 | 5.84 | | ≤2365.2 | 10 | 8196.79 | 6410.02 | 484.27 | 13114.41 | 10.66 | | ≤3547.8 | 55 | 3350.52 | 1252.39 | 791.36 | 4122.04 | 9.21 | | >3547.8 | 13 | 3416.75 | 1469.23 | 1469.23 | 4403.86 | 10.93 | |
|
|
test of two independent samples. test of multigroup independent samples.
|